




Mateon Therapeutics
Investor Relations Department
701 Gateway Blvd, Suite 210
S. San Francisco, CA 94080
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

OT: MATN

| | |
|---------------|---|
| Last Trade: | 0.22 |
| Trade Time: | 10:49 AM ET Jun 19, 2018 |
| Change: | -0.01  (-5.875%) |
| Day Range | 0.22 - 0.24 |
| 52-Week Range | 0.09 - 0.55 |
| Volume | 467,100 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.


Company Profile

We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide. We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.

Our common stock is traded on the OTCQX Market under the symbol "MATN".

We are head... [\(more\)](#)

Stock Quote



Press Releases [\[View all \]](#)

- May 14, 2018*
[Mateon Therapeutics Reports First Quarter 2018 Financial Results](#)
- Apr 16, 2018*
[Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results](#)
- Apr 16, 2018*
[Mateon Therapeutics Raises Net Proceeds of Approximately \\$2.4 Million in Financing Transaction](#)
- Jan 8, 2018*
[Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors](#)
- Jan 3, 2018*
[Mateon Therapeutics to Present at the 2018 Biotech Showcase](#)

Financials & Filings [\[View all \]](#)

- Apr 17, 2018*
[Annual Report \(10-K\)](#)
- May 7, 2018*
[Proxy Statement \(DEF 14A\)](#)
- May 14, 2018*
[Quarterly Report \(10-Q\)](#)
- Nov 14, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*
[Quarterly Report \(10-Q\)](#)